CL2015000732A1 - Un metodo para inhibir o reducir daño talamico en un sujeto afectado por esclerosis multiple que comprende la administracion de laquinimod; composicion farmaceutica. - Google Patents
Un metodo para inhibir o reducir daño talamico en un sujeto afectado por esclerosis multiple que comprende la administracion de laquinimod; composicion farmaceutica.Info
- Publication number
- CL2015000732A1 CL2015000732A1 CL2015000732A CL2015000732A CL2015000732A1 CL 2015000732 A1 CL2015000732 A1 CL 2015000732A1 CL 2015000732 A CL2015000732 A CL 2015000732A CL 2015000732 A CL2015000732 A CL 2015000732A CL 2015000732 A1 CL2015000732 A1 CL 2015000732A1
- Authority
- CL
- Chile
- Prior art keywords
- laquinimod
- inhibiting
- administration
- pharmaceutical composition
- multiple sclerosis
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title 1
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title 1
- 229960004577 laquinimod Drugs 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000000542 thalamic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dispersion Chemistry (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713256P | 2012-10-12 | 2012-10-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015000732A1 true CL2015000732A1 (es) | 2015-08-07 |
Family
ID=50475887
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015000732A CL2015000732A1 (es) | 2012-10-12 | 2015-03-23 | Un metodo para inhibir o reducir daño talamico en un sujeto afectado por esclerosis multiple que comprende la administracion de laquinimod; composicion farmaceutica. |
| CL2016002873A CL2016002873A1 (es) | 2012-10-12 | 2016-11-11 | Composición farmacéutica para reducir el daño talámico. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016002873A CL2016002873A1 (es) | 2012-10-12 | 2016-11-11 | Composición farmacéutica para reducir el daño talámico. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20140107154A1 (enExample) |
| EP (1) | EP2961406A4 (enExample) |
| JP (1) | JP2015533163A (enExample) |
| KR (1) | KR20150080509A (enExample) |
| CN (1) | CN105263325A (enExample) |
| AR (1) | AR092993A1 (enExample) |
| AU (2) | AU2013329348A1 (enExample) |
| BR (1) | BR112015007782A2 (enExample) |
| CA (1) | CA2884272A1 (enExample) |
| CL (2) | CL2015000732A1 (enExample) |
| EA (1) | EA201590726A1 (enExample) |
| HK (1) | HK1218865A1 (enExample) |
| IL (1) | IL237745A0 (enExample) |
| MX (1) | MX2015004564A (enExample) |
| PE (1) | PE20151435A1 (enExample) |
| SG (1) | SG11201501874TA (enExample) |
| TW (1) | TW201420101A (enExample) |
| WO (1) | WO2014058979A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015505564A (ja) | 2012-02-03 | 2015-02-23 | テバ ファーマシューティカル インダストリーズ リミティド | 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用 |
| JP6215238B2 (ja) | 2012-02-16 | 2017-10-18 | テバ ファーマシューティカル インダストリーズ リミティド | Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| MX2015010296A (es) * | 2013-02-15 | 2016-05-05 | Teva Pharma | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. |
| EP3082814A4 (en) * | 2013-12-20 | 2017-06-21 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod to delay huntington's disease progression |
| AU2015253330A1 (en) | 2014-04-29 | 2016-12-01 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
| MX386778B (es) | 2015-03-09 | 2025-03-19 | Intekrin Therapeutics Inc | Métodos para el tratamiento de enfermedad de hígado graso no alcohólico y/o lipodistrofia. |
| WO2017048457A1 (en) * | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| EP3512512A4 (en) * | 2016-09-13 | 2020-06-03 | Intekrin Therapeutics, Inc. | TREATMENT OF MULTIPLE SCLEROSIS WITH CHS-131 |
| CA3058806A1 (en) | 2017-04-03 | 2018-10-11 | Coherus Biosciences Inc. | Ppar.gamma. agonist for treatment of progressive supranuclear palsy |
| CN113397757A (zh) * | 2021-06-07 | 2021-09-17 | 温州医科大学 | 用于测试拉喹莫德在治疗缺血性脑卒中的作用的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1850840A2 (en) * | 2005-01-13 | 2007-11-07 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
| MX2009000645A (es) * | 2006-07-17 | 2009-03-06 | Novartis Ag | Derivados de sulfonilaminocarbonilo de amidas de acido biliar para utilizarse en la forma de inmunomoduladores. |
| TW201014605A (en) * | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
| DK2442651T3 (en) * | 2009-06-19 | 2015-09-21 | Teva Pharma | Treatment of multiple sclerosis with laquinimod |
| PT2467372T (pt) * | 2009-08-10 | 2016-08-23 | Teva Pharma | Tratamento de distúrbios relacionados com bdnf usando laquinimod |
| US20130035390A1 (en) * | 2010-01-13 | 2013-02-07 | Ramot At Tel-Aviv University Ltd. | Treatment of multiple sclerosis |
| SG10201509831XA (en) * | 2010-12-07 | 2015-12-30 | Teva Pharma | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
| ES2602794T3 (es) * | 2011-03-31 | 2017-02-22 | Pfizer Inc | Piridinonas bicíclicas novedosas |
| EP2766020A4 (en) * | 2011-10-12 | 2015-04-01 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD |
| AR090885A1 (es) * | 2012-05-02 | 2014-12-10 | Teva Pharma | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |
-
2013
- 2013-10-09 US US14/049,411 patent/US20140107154A1/en not_active Abandoned
- 2013-10-09 EP EP13895446.6A patent/EP2961406A4/en not_active Withdrawn
- 2013-10-09 AU AU2013329348A patent/AU2013329348A1/en not_active Abandoned
- 2013-10-09 PE PE2015000472A patent/PE20151435A1/es not_active Application Discontinuation
- 2013-10-09 BR BR112015007782A patent/BR112015007782A2/pt active Search and Examination
- 2013-10-09 CN CN201380053184.1A patent/CN105263325A/zh active Pending
- 2013-10-09 SG SG11201501874TA patent/SG11201501874TA/en unknown
- 2013-10-09 EA EA201590726A patent/EA201590726A1/ru unknown
- 2013-10-09 MX MX2015004564A patent/MX2015004564A/es unknown
- 2013-10-09 CA CA2884272A patent/CA2884272A1/en not_active Abandoned
- 2013-10-09 WO PCT/US2013/064061 patent/WO2014058979A2/en not_active Ceased
- 2013-10-09 JP JP2015536853A patent/JP2015533163A/ja active Pending
- 2013-10-09 HK HK16106893.7A patent/HK1218865A1/zh unknown
- 2013-10-09 KR KR1020157012465A patent/KR20150080509A/ko not_active Withdrawn
- 2013-10-11 AR ARP130103705A patent/AR092993A1/es unknown
- 2013-10-11 TW TW102136847A patent/TW201420101A/zh unknown
-
2015
- 2015-03-15 IL IL237745A patent/IL237745A0/en unknown
- 2015-03-23 CL CL2015000732A patent/CL2015000732A1/es unknown
-
2016
- 2016-06-17 US US15/186,163 patent/US20160296511A1/en not_active Abandoned
- 2016-11-11 CL CL2016002873A patent/CL2016002873A1/es unknown
-
2017
- 2017-06-08 AU AU2017203896A patent/AU2017203896A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1218865A1 (zh) | 2017-03-17 |
| CA2884272A1 (en) | 2014-04-17 |
| WO2014058979A3 (en) | 2015-08-20 |
| US20140107154A1 (en) | 2014-04-17 |
| IL237745A0 (en) | 2015-05-31 |
| EP2961406A2 (en) | 2016-01-06 |
| KR20150080509A (ko) | 2015-07-09 |
| CN105263325A (zh) | 2016-01-20 |
| PE20151435A1 (es) | 2015-10-15 |
| SG11201501874TA (en) | 2015-05-28 |
| WO2014058979A8 (en) | 2015-04-16 |
| MX2015004564A (es) | 2015-07-21 |
| BR112015007782A2 (pt) | 2017-07-04 |
| EA201590726A1 (ru) | 2015-10-30 |
| CN105263325A8 (zh) | 2017-07-14 |
| WO2014058979A2 (en) | 2014-04-17 |
| AR092993A1 (es) | 2015-05-13 |
| US20160296511A1 (en) | 2016-10-13 |
| TW201420101A (zh) | 2014-06-01 |
| CL2016002873A1 (es) | 2017-04-17 |
| AU2017203896A1 (en) | 2017-06-29 |
| AU2013329348A1 (en) | 2015-05-28 |
| EP2961406A4 (en) | 2017-01-04 |
| JP2015533163A (ja) | 2015-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015000732A1 (es) | Un metodo para inhibir o reducir daño talamico en un sujeto afectado por esclerosis multiple que comprende la administracion de laquinimod; composicion farmaceutica. | |
| BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
| BR112014010179A8 (pt) | composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição | |
| CL2014002077A1 (es) | Composicion farmaceutica que comprende fumarato de dimetilo; metodo de preparacion; capsula que comprende microtabletas de fumarato de dimetilo; metodo para el tratamiento, profilaxis o mejora de la esclerosis multiple. | |
| BR112015001098A2 (pt) | composto, composição farmacêutica e método para o tratamento de uma condição de doença. | |
| BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
| BR112014003681A8 (pt) | composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições | |
| BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
| BR112014011671A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto | |
| BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BR112015002541A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente. | |
| BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| CL2014000209A1 (es) | Metodo para tratar esclerosis multiple que comprende el uso de laquinimod y acetato de glatiramero y kit que comprende composiciones farmaceuticas conteniendo a ambos compuestos independientemente. | |
| DK3192501T3 (da) | Topisk farmaceutisk sammensætning baseret på semifluorerede alkaner | |
| BR112014003801A2 (pt) | composto, composição farmacêutica, e, métodos para a inibição de romk, para a provocação de diurese, natriurese ou ambas, e para o tratamento ou a profilaxia de um ou mais distúrbios | |
| BR112013020362A2 (pt) | processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem | |
| BR112014031263A2 (pt) | composto, composição farmacêutica, métodos para inibir a secreção wnt e para inibir sinalização wnt, uso do composto ou sal e método para tratar um distúrbio. | |
| BR112014032510A2 (pt) | composto, composição farmacêutica, método para tratar ou prevenir uma doença ou desordem, e, uso de um composto. | |
| BR112014031896A2 (pt) | composto, composição farmacêutica, e, método para o tratamento de um distúrbio | |
| BR112014026149A2 (pt) | método para a preparação de 2,4-ácido dihidroxibutírico (2,4-dhb) e microrganismo. | |
| BR112014006420A2 (pt) | compostos, composição farmacêutica, uso de um composto e mètodo para o tratamento ou profilaxia | |
| CL2014003503A1 (es) | Composición farmacéutica para uso intramamario que comprende un ácido fosfónico y al menos un agente antimicrobiano; y uso para el tratamiento o prevención de mastitis en mamífero no humano. | |
| BR112014031899A8 (pt) | composto, composição farmacêutica, e, método para tratamento de um distúrbio | |
| CL2013002026A1 (es) | Compuesto solido (r)-1-etil-3-[5-[2-(1-hidroxi-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzimidazol-2-il]-urea y metodo para prepararla. | |
| BR112014016736A2 (pt) | composto, composição farmacêutica, método para tratamento, uso de um composto e invenção |